Award

Inherited Risk Factors for Breast Cancer

Description: Germline pathogenic variants (PV) in BRCA2 and other predisposition genes are associated with increased risks of breast cancer. However, certain types of mutations termed variants of uncertain significance (VUS) that are identified in these genes by hereditary cancer genetic testing cause problems because their involvement in cancer is not understood. As a result, those with VUS cannot benefit from improved clinical management in the same way as those with well-defined PVs. For instance, these individuals do not qualify for enhanced cancer screening with mammograms and MRI or from targeted treatment of breast cancer with PARP inhibitor therapy. We have recently used CRISPR/cas9 targeting studies to determine the clinical relevance of all possible VUS in the BRCA2, PALB2, RAD51D and ATM genes. Among these we have identified hundreds that seem to have partial effects on gene function. These “hypomorphic” variants likely yield partial, moderate risks of breast cancer. Individuals with these variants may need different management than individuals with full pathogenic variants. We propose to confirm these effects in other laboratory tests, and to develop accurate estimates of the predicted reduced cancer risks associated with these variants. In addition, we will conduct further analysis of variants in a previously understudied part of the ATM gene and in the RAD51D gene. The results will be directly used for management of the clinical care of individuals with both pathogenic and hypomorphic variants.
Amount: $450,000
Funding type: award
Start date: 2026-10-01
End date: 2028-09-30
Investigator: Fergus Couch (lead)
Institutions: Mayo Clinic, MAYO CLINIC, ROCHESTER, MN
Subfield: Genetics
Funded outputs count: 1
Funder award ID: BCRF-26-030
OpenAlex ID: G9000361862